Neurology, Год журнала: 2024, Номер 104(2)
Опубликована: Дек. 23, 2024
To compare the diagnostic performance of an immunoassay for plasma concentrations phosphorylated tau (p-tau) 217 with visual assessments fluorine-18 fluorodeoxyglucose [
Язык: Английский
Brain, Год журнала: 2025, Номер unknown
Опубликована: Янв. 6, 2025
Blood-based biomarkers for Alzheimer's disease (AD) pathology have been intensively investigated as markers AD-related neurodegeneration. Comorbid AD is common in dementia with Lewy bodies (DLB). Accordingly, we hypothesized that plasma associated might be useful to predict DLB a cohort of idiopathic/isolated REM sleep behavior disorder (iRBD), an incipient synucleinopathy. The aim this study was determine whether amyloid-β and pTau181 can DLB. This longitudinal single-center (Canada) included 158 polysomnography-confirmed iRBD individuals between September 2004 October 2022, each providing blood samples, who were then offered prospective follow-up. Plasma Aβ40, Aβ42 levels measured using NeuroToolKit, prototype assays panel neurodegeneration (Roche Diagnostics International Ltd). primary outcome the association at baseline eventual development Correlations cognitive tests assessed. A total 142 participants (109 men [77%], mean ± SD age, 67.6 8.0 years) final analysis. On follow-up (2.9 2.1 years after sampling), 32 phenoconverted defined neurodegenerative syndrome (18 DLB, 13 PD, 1 MSA). combined phenoconvertor group had lower Aβ42/40 ratio compared non-phenoconvertors (mean SD, 0.103 0.010 vs. 0.114 0.012, p < 0.001), higher (0.993 0.354 0.784 0.266pg/ml, = 0.008). When divided by phenoconversion subtype, significant differences seen selectively DLB-convertors (Aβ42/40 0.101 0.010, difference -0.011, 95% CI [-0.016; -0.005], 0.001; 1.144 0.326 pg/ml, 0.282 [0.146; 0.418], 0.001). Cross-sectional analysis showed (but not Aβ42/40) correlated across various domains. Our results indicate conversion iRBD.
Язык: Английский
Процитировано
4
Alzheimer s & Dementia, Год журнала: 2024, Номер 20(4), С. 2485 - 2496
Опубликована: Фев. 8, 2024
Abstract INTRODUCTION Patients with dementia Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate biomarkers of AD and their association positron emission tomography (PET) amyloid tau deposition in the continuum DLB, starting from prodromal stages disease. METHODS The cohort included patients isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment (MCI‐LB), or a concurrent blood draw PET scans. RESULTS Abnormal levels glial fibrillary acidic protein (GFAP) were found at stage MCI‐LB increased PET. phosphorylated (p‐tau)‐181 neurofilament light (NfL) DLB stage. Plasma p‐tau‐181 showed highest accuracy detecting abnormal DLB. DISCUSSION range co‐pathology continuum, particularly GFAP.
Язык: Английский
Процитировано
15
Ageing Research Reviews, Год журнала: 2024, Номер 96, С. 102290 - 102290
Опубликована: Апрель 1, 2024
Язык: Английский
Процитировано
13
Brain, Год журнала: 2024, Номер 147(10), С. 3325 - 3343
Опубликована: Июль 11, 2024
Concomitant Alzheimer's disease (AD) pathology is a frequent event in the context of Lewy body (LBD), occurring approximately half all cases. Evidence shows that LBD patients with AD copathology show an accelerated course, greater risk cognitive decline and overall poorer prognosis. However, LBD-AD cases may heterogeneous motor non-motor phenotypes higher dementia and, consequently, be not rarely misdiagnosed. In this review, we summarize current understanding by discussing synergistic effects neuropathological changes their clinical relevance. Furthermore, provide extensive overview neuroimaging fluid biomarkers under assessment for use possible diagnostic prognostic values. can predicted vivo means CSF, MRI PET markers, whereas most promising technique to date identifying different biological tissues α-synuclein seed amplification assay. Pathological imaging CSF are associated likelihood but do always mirror severity as pure AD. Implementing blood-based might allow faster screening copathology, thus improving sensitivity LBD-AD. Finally, discuss literature on novel candidate being exploited investigate other aspects neurodegeneration, such neuroaxonal injury, glial activation synaptic dysfunction. The thorough characterization should taken into account when considering differential diagnoses syndromes, evaluation individual level, guide symptomatic disease-modifying therapies.
Язык: Английский
Процитировано
12
Alzheimer s & Dementia, Год журнала: 2025, Номер 21(5)
Опубликована: Май 1, 2025
Abstract INTRODUCTION Despite ongoing debate about whether Parkinson's disease (PD) dementia (PDD) and with Lewy bodies (DLB) are separable diseases or a single body (LBD) spectrum, there limited investigations of differences between these conditions. METHODS We used fixel‐based diffusion magnetic resonance imaging plasma measures to examine white matter integrity burden amyloid pathology (using phosphorylated tau‐217 [p‐tau217]) in 47 patients DLB, 21 PDD, 29 PD, 23 age‐matched controls. RESULTS show reduced fiber cross‐section LBD versus increased concentrations neurofilament light chain p‐tau217; p‐tau217 associated cognition. Fiber density was PDD but neither nor differed subtypes. DISCUSSION Our findings suggest that the presence is poorer macrostructure may relate pathological protein accumulation. Conversely, DLB be driven by other factors. Highlights Plasma were relative Magnetic (MRI) (fiber cross‐section) PD. In contrast, MRI microstructure density) PD compared bodies. Differences distinct those normal differ underlying processes from driving dementia.
Язык: Английский
Процитировано
1
Drug Design Development and Therapy, Год журнала: 2024, Номер Volume 18, С. 1199 - 1219
Опубликована: Апрель 1, 2024
Aim: Scutellaria baicalensis , a traditional Chinese medicinal herb renowned for its anti-inflammatory, antioxidant, and anti-tumor properties, has shown promise in alleviating cognitive impairment associated with Alzheimer's disease. Nonetheless, the exact neuroprotective mechanism of against disease remains unclear. In this study, network pharmacology was employed to explore possible mechanisms by which protects Methods: The active compounds were retrieved from TCMSP database, their corresponding targets identified. disease-related obtained through searches GeneCards OMIM databases. Cytoscape 3.6.0 software utilized construct regulatory illustrating "active ingredient-target" relationships. Subsequently, target genes affected context input into String database establish PPI network. GO analysis KEGG conducted using DAVID predict potential pathways these key targets. Following this, capacity ingredients bind core confirmed molecular docking. vitro experiments then carried out further validation. Results: A total 36 screened out, corresponded 365 Molecular docking results demonstrated robust binding abilities Baicalein, Wogonin, 5,2'-Dihydroxy-6,7,8-trimethoxyflavone proteins (SRC, PIK3R1, STAT3). showed that components can inhibit STAT3 expression downregulating PIK3R1/SRC pathway Neuro 2A cells. Conclusion: summary, findings collectively suggest holds as viable treatment option Keywords: disease, pharmacology,
Язык: Английский
Процитировано
6
Ageing Research Reviews, Год журнала: 2024, Номер unknown, С. 102514 - 102514
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
4
Alzheimer s & Dementia, Год журнала: 2025, Номер unknown
Опубликована: Янв. 24, 2025
Lewy body dementia (LBD) shares genetic risk factors with Alzheimer's disease (AD), including apolipoprotein E (APOE), but is distinguishable at the genome-wide level. Polygenic scores (PRS) may therefore improve diagnostic classification. We assessed classification using AD-PRS excluding APOE (AD-PRSno APOE), score (APOE-RS), and plasma phosphorylated tau 181 (p-tau181), in 83 participants LBD, 27 positron emission tomography amyloid beta (Aβ)positive mild cognitive impairment or AD (MCI+/AD), 57 controls. Together AD-PRSno APOE-RS performed similarly to p-tau181 discriminating MCI+/AD from controls (area under curve 76% vs. 79%) LBD (71% 72%). In Aβ positivity was significantly associated APOE-RS, not APOE, p-tau181. Combining improved discrimination of (81%) (75%), detection (82%). deposition while also beyond APOE. explains phenotypic variance captured by investigated (AD) polygenic (PRS), (p-tau181) classify (LBD). achieved similar accuracy without contributed LBD. Amyloid AD-PRS, accuracy.
Язык: Английский
Процитировано
0
Movement Disorders, Год журнала: 2025, Номер unknown
Опубликована: Март 29, 2025
Little is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI-LB). To investigate association four disease progression MCI. Plasma amyloid-beta (Aβ)42/40, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau 181 (pTau181) were measured at baseline a longitudinal MCI cohort (n = 131). Baseline NfL was associated increased risk dementia/death entire cohort. In MCI-LB, NfL, GFAP, pTau181 decline by Addenbrooke's Cognitive Examination-Revised. pTau181, are more rapid MCI-LB and, further validation, could be useful to support prognosis stratification for clinical practice treatment trials. Further work, including clinicopathological studies, needed understand biological correlates these markers MCI-LB. © 2025 The Author(s). Movement Disorders published Wiley Periodicals LLC on behalf International Parkinson Disorder Society.
Язык: Английский
Процитировано
0
Journal of Neurology, Год журнала: 2025, Номер 272(4)
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0